Adding olanzapine to valproic acid.
- Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.
- Olanzapine is principally metabolized by CYP1A2 and CYP2D6.
- Start olanzapine according to the general dosing advice. Monitoring of the liver function every 3 to 4 months during the first year of treatment with either olanzapine or valproic acid is recommended.
- Concurrent use of olanzapine and valproic acid may potentiate the risk of hepatotoxicity.
↑ 1.01.1 Farmacotherapeutisch Kompas; Toxicologie (dutch)
Cite error: Invalid
<ref>tag; name "ftktox" defined multiple times with different content
- ↑ Farmacotherapeutisch Kompas - valproinezuur (dutch)
↑ 3.03.13.23.33.4 KNMP; Informatorium Medicamentorum 2015; Monografie "valproaat" (Dutch)
Cite error: Invalid
<ref>tag; name "informatorium" defined multiple times with different content
- ↑ Woods SW Chlorpromazine equivalent doses for the newer atypical antipsychotics; J Clin Psychiatry 2003;64:663-667
- ↑ 5.05.1 Interactions between olanzapine and valproic acid on drugs.com
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.